U-Blot® Research Grade Tirnovetmab

Background：Tirnovetmab (KIND-016) is an antibody. Tirnovetmab can be used for experiment research.
• The IL-4, IL-13 and IL-31 pathways in atopic dermatitis., PMID:34106037
• IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis., PMID:37831760
• Interleukin-31: The “itchy” cytokine in inflammation and therapy., PMID:33629401
• A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1., PMID:24373353
• Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis., PMID:38117036
• Nemolizumab: First Approval., PMID:35834124
• Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis., PMID:35842249
• The Cytokine TGF-β Induces Interleukin-31 Expression from Dermal Dendritic Cells to Activate Sensory Neurons and Stimulate Wound Itching., PMID:32673566
• Pruritus as a Distinctive Feature of Type 2 Inflammation., PMID:33807098
• Targeting Interleukin-31 in Prurigo., PMID:37888922